Latest filing published 17 Mar 2020 for Fusion Antibodies plc, €13k.
Filing timeline
BuySaleInsider track record
Closed purchases
Based on 5 purchases whose 90-day window has closed (published at least 91 days ago), the same population our ranking model reads.
Purchases by company
Since each purchase
- +164.5%Entry £0.61 · Close at T+365 £1.60
- +163.2%Entry £0.67 · Close at T+365 £1.75
- +32.1%Entry £0.66 · Close at T+365 £0.86
- +49.5%Entry £0.53 · Close at T+365 £0.79
- -4.3%Entry £0.71 · Close at T+365 £0.68
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
Alan Mawson: trading record in brief
This profile gathers the share dealings of Alan Mawson in Fusion Antibodies plc. The record holds 7 filings, for trades running from 24 September 2018 to 16 March 2020.
The open-market record is one-sided, with 7 purchases worth €76k and not one sale. Unlike grants, an open-market purchase is paid for by the insider, at the market price. In 2020 alone, the filings show 2 purchases and no sales.
In size, the median ticket on the buying side is €11k. Clusters matter here: 2 out of 5 purchases overlapped with buying by a colleague within 30 days. Such overlaps are known as a cluster signal: distinct people reaching the same decision at about the same time. Looking at 5 purchases old enough to measure, the stock rose over the following 90 days in 60% of cases; the median change was +1.5%. This is a record of the past, not a forecast.
The newest entry dates from 17 March 2020: an open-market purchase of €13k, in Fusion Antibodies plc. Typically, a trade is published a median of 1 day after it takes place. For comparison, UK MAR gives managers three business days to notify a trade. These figures are compiled from regulatory filings published by RNS (LSE). They describe what insiders did and are not a recommendation.
Companies and markets linked to Alan Mawson
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
- 20,000 shares@ £0.60100.0% of flowLondon Stock Exchange, XLONISIN GB00BDQZGK16FCA-NSM:LSE20200317070008_3528937_20200331164957099_17551Canonical exit: 14 Jun 2020 (T+90)
- 20,000 shares@ £0.77London Stock Exchange, XLONISIN GB00BDQZGK16FCA-NSM:LSE20200110114754_14379874_20200331164951868_9774Canonical exit: 7 Apr 2020 (T+90)
- 20,000 shares@ £0.75London Stock Exchange, XLONISIN GB00BDQZGK16FCA-NSM:LSE20191203092614_14332734_20200326185106334_28730Canonical exit: 1 Mar 2020 (T+90)
- 15,000 shares@ £0.6545.2% of flowLondon Stock Exchange, XLONISIN GB00BDQZGK16FCA-NSM:LSE20190926095422_14242712_20200326185201885_4999Canonical exit: 25 Dec 2019 (T+90)
- 10,000 shares@ £0.5916.4% of flowLondon Stock Exchange, XLONISIN GB00BDQZGK16FCA-NSM:LSE20190703160914_14135577_20200326185125204_34467-1Canonical exit: 30 Sept 2019 (T+90)
- 5,000 shares@ £0.52510.8% of flowLondon Stock Exchange, XLONISIN GB00BDQZGK16FCA-NSM:LSE20181203133902_13889315_20200330111407806_1258Canonical exit: 28 Feb 2019 (T+90)
- 8,500 shares@ £0.6718.9% of flowLondon Stock Exchange, XLONISIN GB00BDQZGK16FCA-NSM:LSE20180925142357_13804051_20200330111446177_4543-0Canonical exit: 23 Dec 2018 (T+90)
7 of 7 declarations